Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.
The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report includes new data on IL-1 and pregnancy, contraceptives and the risk of RA, Calprotectin the biomarker, T2T failing, and the loss of a giant in rheumatology.
Dr. H. Ralph Schumacher passed away from ALS in July 30, 2017. The current issues of The Rheumatologist and the Journal of Clinical Rheumatology have beautiful tributes written by Dr. Simon Helfgott and past ACR president Dr.
Non-Tuberculous Mycobacterial infections are among the most frequently reported opportunistic infections in the setting of biologic therapy. While there are hundreds of NTM species, only a minority are clinically relevant. In this review, I'll address important NTM diagnosis and management issues relevant to patients receiving biologic therapy.
Golimumab (GOL) is one of five marketed TNF inhibitors (TNFi) that is FDA approved for use in psoriatic arthritis (PsA).
Treat-to-target strategy is widely advocated as an important means of optimizing treatment responses in patients with rheumatoid arthritis. Even though T2T is encouraged by most guidelines, a current report shows that US Rheumatologists fail to implement T2T in their daily practice.
Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.
In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA.
Studies have shown that rheumatoid arthritis (RA) patients have increased risk of acute coronary syndrome (ACS) and may suffer from poorer short-term outcomes after ACS. The long-term outcomes in patients with RA with ACS was shown to be worse than matched non-RA patients also with ACS.
In 1994 there were 600 supplement companies, producing 4,000 OTC supplement products for a total revenue of about $4 billion. Today we have close to 6,000 companies, producting nearly 75,000 supplement products, bringing in $37 billion annually.
The introduction of intravenous pegloticase (PEG) in 2010 was felt by many to be a major advance in the treatment of patients with severe, refractory tophaceous gout. But for some, concerns over infusion reactions and safety have limited its use.
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
